Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

被引：74

作者：

Saciuk, Yaki ^{[1
]}

Kertes, Jennifer ^{[1
]}

Stein, Naama Shamir ^{[1
]}

Zohar, Anat Ekka ^{[1
]}

机构：

[1] Maccabi HealthCare Serv, Div Data & Digital Hlth, Tel Aviv, Israel

来源：

JOURNAL OF INFECTIOUS DISEASES | 2022年 / 225卷 / 01期

关键词：

vaccine effectiveness; COVID-19; SARS-CoV-2; Pfizer-BioNTech vaccine; mRNA BNT162b2; COVID-19; VACCINE; ISRAEL; IMPACT;

D O I：

10.1093/infdis/jiab556

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January-February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August-October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%-93.2%) and adjusted VE was 89.1% (95% CI, 87.5%-90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.

引用

页码：30 / 33

页数：4

共 9 条

[1] Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Yinon M.
Goldberg, Yair
Mandel, Micha
Bodenheimer, Omri
Freedman, Laurence
Kalkstein, Nir
Mizrahi, Barak
Alroy-Preis, Sharon
Ash, Nachman
Milo, Ron
Huppert, Amit
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) : 1393 - 1400
[2] BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, Noa
Barda, Noam
Kepten, Eldad
Miron, Oren
Perchik, Shay
Katz, Mark A.
Hernan, Miguel A.
Lipsitch, Marc
Reis, Ben
Balicer, Ran D.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) : 1412 - 1423
[3] Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Haas, Eric J.
Angulo, Frederick J.
McLaughlin, John M.
Anis, Emilia
Singer, Shepherd R.
Khan, Farid
Brooks, Nati
Smaja, Meir
Mircus, Gabriel
Pan, Kaijie
Southern, Jo
Swerdlow, David L.
Jodar, Luis
Levy, Yeheskel
Alroy-Preis, Sharon
[J]. LANCET, 2021, 397 (10287) : 1819 - 1829
[4] Kertes J, 2021, EMERG INFECT DIS, DOI [10.1101/2021.09.01.21262957, DOI 10.1101/2021.09.01.21262957]
[5] COVID-19 vaccine impact in Israel and a way out of the pandemic
Leshem, Eyal
Wilder-Smith, Annelies
[J]. LANCET, 2021, 397 (10287) : 1783 - 1785
[6] Patalon T, 2021, SHORT TERM REDUCTION, DOI 10.1101/2021.08.29.21262792
[7] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, Fernando P.
Thomas, Stephen J.
Kitchin, Nicholas
Absalon, Judith
Gurtman, Alejandra
Lockhart, Stephen
Perez, John L.
Perez Marc, Gonzalo
Moreira, Edson D.
Zerbini, Cristiano
Bailey, Ruth
Swanson, Kena A.
Roychoudhury, Satrajit
Koury, Kenneth
Li, Ping
Kalina, Warren V.
Cooper, David
Frenck, Robert W., Jr.
Hammitt, Laura L.
Tureci, Ozlem
Nell, Haylene
Schaefer, Axel
Unal, Serhat
Tresnan, Dina B.
Mather, Susan
Dormitzer, Philip R.
Sahin, Ugur
Jansen, Kathrin U.
Gruber, William C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) : 2603 - 2615
[8] Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine
Tanne, Janice Hopkins
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 371 : m4799
[9] Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Tartof, Sara Y.
Slezak, Jeff M.
Fischer, Heidi
Hong, Vennis
Ackerson, Bradley K.
Ranasinghe, Omesh N.
Frankland, Timothy B.
Ogun, Oluwaseye A.
Zamparo, Joann M.
Gray, Sharon
Valluri, Srinivas R.
Pan, Kaije
Angulo, Frederick J.
Jodar, Luis
McLaughlin, John M.
[J]. LANCET, 2021, 398 (10309) : 1407 - 1416

← 1 →